Archives

Vaaka Partners strengthens team with new Partner and new Associate

Friday 29.01.2021

Vaaka Partners strengthens its investment team with two new recruits both starting in February. Mr Jarkko Murtoaro has been invited to join the team as Partner after 13 years at EQT. Mr Jesper Kontinen joins the team as Associate with prior experience from Goldman Sachs and McKinsey & Company.

Jarkko Murtoaro is well-known to the Vaaka team from his role at EQT, leading the Nordic pet care specialist Musti Group’s value creation towards its successful IPO. Vaaka Partners sold the majority stake of Musti Group to EQT 6 years ago but retained a minority shareholding during EQT’s ownership. Jarkko’s background includes investment banking with Citigroup in London before joining EQT in September 2007. During his time at EQT, Jarkko worked both in the Helsinki and Stockholm offices, and his latest position was a Managing Director. Jarkko is starting at Vaaka Partners as a Partner on February 1st.

Jarkko comments why he chose to join the firm: “Vaaka has a strong team and a great culture. I am excited to be joining the company and look forward to working with my new colleagues and the management teams of Vaaka companies.”

Jesper Kontinen has a Master of Science degree from the Aalto University Finance programme. Vaaka Partners became familiar to Jesper through our long-standing internship program in the spring of 2018. Thereafter, Jesper moved to London to join Goldman Sachs’ Investment Banking Division and in 2019 relocated back to Finland for a position at McKinsey & Company. Jesper is starting at Vaaka Partners as an Associate on February 1st.

“We are warmly welcoming Jarkko and Jesper to the team. Not only are they brilliant professionals, but also very nice persons and colleagues to collaborate with – an excellent culture fit”, says Juha Peltola, Managing Partner.

For more information

Juha Peltola, Managing Partner
+358 50 514 8401
Juha.peltola@vaakapartners.fi

Categories: People

EQT takes next step in its Asia-Pacific strategy – opens office in Japan

eqt

In line with EQT AB’s strategic roadmap outlined at the IPO in 2019, growing in the Asia-Pacific region is a key focus area. As the next step on that strategy, EQT is happy to announce the establishment of a local EQT Partners office in Japan. The first EQT investment advisory team to establish in Japan is the Private Equity business line with the team based in Tokyo. EQT is in the process of both recruiting local talent and relocating EQT resources to build a team representing both EQT’s DNA and local-with-locals approach.

Christian Sinding, CEO and Managing Partner of EQT AB, says: “Japan is a major and increasingly exciting market for private capital and one of the largest geographic opportunities we have globally. We are now making a long-term commitment to developing EQT’s presence in Japan and believe that our unique value-added approach and industrial heritage will be highly relevant. Core EQT skills such as supporting companies to internationalize, go through a digital transformation and become sustainability leaders, are all areas where we could support many Japanese companies”.

To ensure effective access to the Japanese market, and that EQT’s industrial, growth-focused investment approach is adapted to domestic market conditions, EQT is also delighted to announce that it will collaborate with a local leading private equity firm Japan Industrial Partners (“JIP”). The specific area of focus will be in finding sizable investment opportunities where global expansion is required, mainly in healthcare, TMT, industrial technology and services sectors. JIP has an outstanding track record in the Japanese market and has been in operation since 2002.

Simon Griffiths, Partner and Head of EQT Private Equity Asia-Pacific, says: “The Japanese market is developing rapidly, and we see many examples where EQT’s expertise and approach can support Japanese companies. JIP has a very similar approach to investing, taking a long-term view, and seeking to develop the strategy and operations of each company in close collaboration with management. We look forward to working together with JIP to help create global growth opportunities for Japanese industries.”

The establishment of EQT Partners’ Japan office is subject to obtaining registration under the Financial Instruments and Exchange Act in Japan.

Contact
Simon Griffiths, Partner and Head of EQT Private Equity Asia-Pacific, +65 6978 3833
Nina Nornholm, Head of Communications, +46 70 855 03 56
EQT Press Office, press@eqtpartners.com

About EQT
EQT is a purpose-driven global investment organization with close to three decades of consistent investment performance across multiple geographies, sectors, and strategies. EQT has raised more than EUR 84 billion since inception and had as of December 31, 2020 more than EUR 52 billion in assets under management across 17 active funds within two business segments – Private Capital and Real Assets.

With its roots in the Wallenberg family’s entrepreneurial mindset and philosophy of long-term ownership, EQT is guided by a set of strong values and a distinct corporate culture. EQT manages and advises funds and vehicles that invest across the world with the mission to future-proof companies, generate attractive returns and make a positive impact with everything EQT does.

The EQT AB Group comprises EQT AB (publ) and its direct and indirect subsidiaries, which include general partners and fund managers of EQT funds as well as entities advising EQT funds. EQT has offices in 17 countries across Europe, Asia-Pacific and North America with more than 700 employees.

More info: www.eqtgroup.com

Follow EQT on LinkedIn, Twitter, YouTube and Instagram

Categories: News

Gimv announces share buyback in the context of a share purchase plan for its personnel

GIMV

The Board of Directors of Gimv has decided, in application of Art. 7:215, §1, al. 3 of the Companies Code, to start a share buyback program of 40,000 shares in the framework of a share purchase plan for certain Gimv employees. Gimv will start the buyback program on February 1, 2021 until the targeted volume has been purchased with a final end date of March 15, 2021.

The buyback program will be conducted in accordance with applicable regulations. For this purpose, Gimv will mandate an independent broker to execute the program through open market purchases on Euronext Brussels. The purchased shares will be held as treasury shares until they have been transferred to the personnel.

Gimv will inform the market on the progress of the program in line with the applicable regulations.

Read the full press release:

English – French – Dutch – German
Gimv
Karel Oomsstraat 37, 2018 Antwerpen, Belgium
www.gimv.com

Categories: News

Quadrum Capital acquires a stake in EMM, an innovative supplier of high-performance and productivity-enhancing solutions to international paint-processing industries

Quadrum Capital

From 27 January 2021. Quadrum Capital is a joint shareholder in EMM, an innovative supplier of high-performance and productivity-enhancing solutions to international paint-processing industries – including automotive, aviation, marine and industrial.Peter Oostenenk, Managing Partner at Quadrum Capital: ‘EMM is a fantastic company and a market leader in the international automotive repair business. Boasting growing sales worldwide, the company is known as a quality player. Together, we will raise EMM’s global profile in the coming years.”

https://www.emm.com/en_gb/news/emm-attracts-quadrum-capital-to-accelerate-growth-strategy./

image

Categories: News

Tags:

CapMan to publish its 2020 Financial Statements Bulletin on Thursday 4 February 2021

Capman

CapMan Plc press release
28 January 2021 at 8.30 a.m. EET

CapMan to publish its 2020 Financial Statements Bulletin on Thursday 4 February 2021

CapMan will publish its 2020 Financial Statements Bulletin on Thursday 4 February 2021 around 8.30 a.m. EET. The company will present the results for the review period over a webcast press conference starting at 9.00 a.m. EET accessible at https://capman.videosync.fi/2020-q4-results. The conference will be held in English. The report and presentation material will be available at CapMan’s website (https://www.capman.com/shareholders/financial-reports/).

Webcast participation does not require advance registration. Due to the Covid-19 pandemic, we will not arrange an in-person press conference at our office.

For further information, please contact:
Linda Tierala, Director, Communications and IR, tel. +358 40 571 7895, linda.tierala@capman.com

Webcast:
4 February 2021 at 9.00 a.m. EET
https://capman.videosync.fi/2020-q4-results
About CapMan
CapMan is a leading Nordic private asset expert with an active approach to value creation. We offer a wide selection of investment products and services. As one of the Nordic private equity pioneers, we have developed hundreds of companies and real estate assets and created substantial value in these businesses and assets over the past 30 years. With over €3.5 billion in assets under management, our objective is to provide attractive returns and innovative solutions to investors. We have a broad presence in the unlisted market through our local and specialised teams. Our investment strategies cover Private Equity, Real Estate and Infra. We also have a growing service business that includes procurement services, fundraising advisory, and analysis, reporting and wealth management services. Altogether, CapMan employs around 150 people in Helsinki, Stockholm, Copenhagen, London and Luxembourg. We are a public company listed on Nasdaq Helsinki since 2001 and a signatory of the UN Principles for Responsible Investment (PRI) since 2012. Read more at www.capman.com. 

Categories: News

Signavio to be Acquired By SAP

Apax

27 January 2021

The Apax Digital Fund (“ADF”), DTCP and Summit Partners, today announced they have agreed to sell portfolio company Signavio, a leader in the enterprise business process intelligence and process management space, to SAP. The transaction is expected to close by Q2 2021, subject to approvals by antitrust authorities. Financial terms of the transaction were not disclosed. Signavio to be Acquired By SAP

Founded in 2009, Signavio is a leading provider of SaaS-based business-process analysis and decision-management software that helps companies design, implement, analyse and manage complex processes, decisions and workflows. Signavio’s Business Process Intelligence Suite includes a centralised collaborative hub and three core product offerings : ‘Signavio Process Manager’, which allows customers to design and build process and decision models; ‘Signavio Workflow Accelerator’ which transforms business process models into standardised workflows; and ‘Signavio Process Intelligence’, which ingests transactional data from customers’ systems to analyse and optimise processes.

Following the 2019 investment round, led by ADF with participation from DTCP, Signavio has achieved high growth while continuing to deliver its innovative business transformation suite to over one million users worldwide.

Dan O’Keefe, Managing Partner of Apax Digital, said: “We are pleased to announce the sale of Signavio. When ADF invested, we backed an incredible management team, led by CEO and co-founder Gero Decker, in what we knew was a stand-out offering in an exciting space. The progress we’ve made together in partnership, against such a dynamic backdrop, is humbling to have witnessed.” Mark Beith, Partner of Apax Digital, added: “It has been a pleasure working with Gero and the whole Signavio family, we’re thrilled by the rapid progress we’ve made together, and wish them all the best for the future in partnership with SAP.”

Matthias Allgaier, Managing Director with Summit Partners, added: “Summit partnered with Signavio in 2015 as the company’s first institutional investor, and over the course of the last five years we have been fortunate to have a front row seat to this great growth story. The company has grown significantly in that time, expanding its geographic reach and impact to serve more than 1 million users across 2,000 organizations around the world. Today, we want to celebrate the vision and execution of Gero and the entire Signavio team – and to recognize the beginning of a new chapter on their growth journey.”

Thomas Preuss, Partner at DTCP, commented: “We knew Gero and his team long before we invested and always believed in their ability to deliver the strong growth and fast developments of recent years. This transaction is a testament to the great work of the team, and we are delighted that a German corporation like SAP is acquiring a German leader in Enterprise SaaS. We are happy that DTCP Growth could team up with Apax to become part of this tremendous success story.”

ENDS

About Signavio
Over 1 million users in more than 2,000 organizations worldwide rely on Signavio’s unique offering to make process part of their DNA. With its powerful mining, modelling and automation capabilities, Signavio’s Business Process Intelligence Suite is a cloud-based management platform that enables mid-size and large organizations to understand, improve and transform all of their business processes faster than ever and at scale, providing new levels of business process speed and real-time intelligence. Its intelligent decision-making tools address digital transformation, operational excellence and customer centricity, placing them at the heart of the world’s leading organizations. Headquartered in Berlin, with offices in the US, UK, France, Netherlands, Switzerland, Sweden, Canada, Singapore, Japan, India and Australia, Signavio has helped optimize over 2 million processes across the globe. The company is backed by Apax Digital, DTCP and Summit Partners. For more information, visit www.signavio.com.

About the Apax Digital Fund
The Apax Digital Fund specializes in growth equity and buyout investments in high-growth enterprise software, consumer internet, and technology-enabled services companies worldwide. The Apax Digital team leverages Apax Partners’ deep tech investing expertise, global platform, and specialized operating experts, to enable technology companies and their management teams to accelerate the achievement of their full potential. For further information, please visit digital.apax.com.

Over its more than 40-year history, Apax Partners has raised and advised funds with aggregate commitments of c.$50 billion. These funds provide long-term equity financing to build and strengthen world-class companies. For more information see: www.apax.com.

About DTCP
DTCP is an investment management firm focused on growth equity and digital infrastructure. Founded in 2015, the firm has raised more than $1 billion in funds from corporate and institutional investors and invested in over 60 companies. DTCP Growth invests in leading enterprise application and infrastructure software companies. To learn more about DTCP, please visit dtcp.capital.

About Summit Partners
Founded in 1984, Summit Partners is a global alternative investment firm that is currently managing more than $23 billion in capital dedicated to growth equity, fixed income and public equity opportunities. Summit invests across growth sectors of the economy and has invested in more than 500 companies in technology, healthcare and other growth industries. Summit maintains offices in North America and Europe and invests in companies around the world. For more information, please see www.summitpartners.com or follow on LinkedIn.

In the United States of America, Summit Partners operates as an SEC-registered investment advisor. In the United Kingdom, this document is issued by Summit Partners LLP, a firm authorized and regulated by the Financial Conduct Authority. Summit Partners LLP is a limited liability partnership registered in England and Wales with registered number OC388179 and its registered office is at 11-12 Hanover Square, London, W1S 1JJ, UK. This document is intended solely to provide information regarding Summit Partners’ potential financing capabilities for prospective portfolio companies.

Media Contacts 

Apax Partners
Katarina Sallerfors / +44 20 7666 6526 / Katarina.Sallerfors@apax.com
Luke Charalambous / +44 20 7872 6494 / Luke.Charalambous@apax.com
Matthew Goodman / James Madsen, Greenbrook | +44 20 7952 2000 | apax@greenbrookpr.com

DTCP
John Klein
john.klein@dtcp.capital
+49 160 680 9906

Summit Partners
Meg Devine
mdevine@summitpartners.com
+1 617 824 1047

 

Categories: News

Tags:

Signavio Acquired By SAP

DTCP

The Apax Digital Fund (“ADF”), DTCP and Summit Partners, today announced they have agreed to sell portfolio company Signavio, a leader in the enterprise business process intelligence and process management space, to SAP

The transaction is expected to close by Q2 2021, subject to approvals by antitrust authorities. Financial terms of the transaction were not disclosed.

Founded in 2009, Signavio is a leading provider of SaaS-based business-process analysis and decision-management software that helps companies design, implement, analyse and manage complex processes, decisions and workflows. Signavio’s Business Transformation Suite includes a centralised collaborative hub and three core product offerings : ‘Signavio Process Manager’, which allows customers to design and build process and decision models; ‘Signavio Workflow Accelerator’ which transforms business process models into standardised workflows; and ‘Signavio Process Intelligence’, which ingests transactional data from customers’ systems to analyse and optimise processes.

Following the 2019 investment round, led by ADF with participation from DTCP, Signavio has achieved high growth while continuing to deliver its innovative business transformation suite to over one million users worldwide.

Dan O’Keefe, Managing Partner of Apax Digital, said: “We are pleased to announce the sale of Signavio. When ADF invested, we backed an incredible management team, led by CEO and co-founder Gero Decker, in what we knew was a stand-out offering in an exciting space. The progress we’ve made together in partnership, against such a dynamic backdrop, is humbling to have witnessed.” Mark Beith, Partner of Apax Digital, added: “It has been a pleasure working with Gero and the whole Signavio family, we’re thrilled by the rapid progress we’ve made together, and wish them all the best for the future in partnership with SAP.”

Matthias Allgaier, Managing Director with Summit Partners, added: “Summit partnered with Signavio in 2015 as the company’s first institutional investor, and over the course of the last five years we have been fortunate to have a front row seat to this great growth story. The company has grown significantly in that time, expanding its geographic reach and impact to serve more than 1 million users across 2,000 organizations around the world. Today, we want to celebrate the vision and execution of Gero and the entire Signavio team – and to recognize the beginning of a new chapter on their growth journey.”

Thomas Preuss, Partner at DTCP, commented: “We knew Gero and his team long before we invested and always believed in their ability to deliver the strong growth and fast developments of recent years. This transaction is a testament to the great work of the team, and we are delighted that a German corporation like SAP is acquiring a German leader in Enterprise SaaS. We are happy that DTCP Growth could team up with Apax to become part of this tremendous success story.”

 

ENDS

 

About Signavio
Over 1 million users in more than 2,000 organizations worldwide rely on Signavio’s unique offering to make process part of their DNA. With its powerful mining, modelling and automation capabilities, Signavio’s Business Transformation Suite is a cloud-based management platform that enables mid-size and large organizations to understand, improve and transform all of their business processes faster than ever and at scale, providing new levels of business process speed and real-time intelligence. Its intelligent decision-making tools address digital transformation, operational excellence and customer centricity, placing them at the heart of the world’s leading organizations. Headquartered in Berlin, with offices in the US, UK, France, Netherlands, Switzerland, Sweden, Canada, Singapore, Japan, India and Australia, Signavio has helped optimize over 2 million processes across the globe. The company is backed by Apax Digital, DTCP and Summit Partners. For more information, visit www.signavio.com.

 

About the Apax Digital Fund
The Apax Digital Fund specializes in growth equity and buyout investments in high-growth enterprise software, consumer internet, and technology-enabled services companies worldwide. The Apax Digital team leverages Apax Partners’ deep tech investing expertise, global platform, and specialized operating experts, to enable technology companies and their management teams to accelerate the achievement of their full potential. For further information, please visit digital.apax.com.

Over its more than 40-year history, Apax Partners has raised and advised funds with aggregate commitments of c.$50 billion. These funds provide long-term equity financing to build and strengthen world-class companies. For more information see: www.apax.com.

 

About DTCP

DTCP is an investment management firm focused on growth equity and digital infrastructure. Founded in 2015, the firm has raised more than $1 billion in funds from corporate and institutional investors and invested in over 60 companies. DTCP Growth invests in leading enterprise application and infrastructure software companies. To learn more about DTCP, please visit dtcp.capital.

 

About Summit Partners
Founded in 1984, Summit Partners is a global alternative investment firm that is currently managing more than $23 billion in capital dedicated to growth equity, fixed income and public equity opportunities. Summit invests across growth sectors of the economy and has invested in more than 500 companies in technology, healthcare and other growth industries. Summit maintains offices in North America and Europe and invests in companies around the world. For more information, please see www.summitpartners.com or follow on LinkedIn.

In the United States of America, Summit Partners operates as an SEC-registered investment advisor. In the United Kingdom, this document is issued by Summit Partners LLP, a firm authorized and regulated by the Financial Conduct Authority. Summit Partners LLP is a limited liability partnership registered in England and Wales with registered number OC388179 and its registered office is at 11-12 Hanover Square, London, W1S 1JJ, UK. This document is intended solely to provide information regarding Summit Partners’ potential financing capabilities for prospective portfolio companies.

 

Media Contacts

 

Apax Partners

Katarina Sallerfors / +44 20 7666 6526 / Katarina.Sallerfors@apax.com

Luke Charalambous / +44 20 7872 6494 / Luke.Charalambous@apax.com

Matthew Goodman / James Madsen, Greenbrook | +44 20 7952 2000 | apax@greenbrookpr.com

 

DTCP

John Klein

john.klein@dtcp.capital

+49 160 680 9906

 

Summit Partners

Meg Devine

mdevine@summitpartners.com

+1 617 824 1047

Categories: News

Tags:

General Atlantic to Invest US$55 Million in Kalbe Genexine Biologics

Capital to fuel Company’s strategic growth into a leading biologics platform in the Southeast Asia region

January 26, 2021

Kalbe Genexine Biologics (“KGBio” or “the Company”), a leading integrated biologics holding company focused on the in-licensing, clinical development,  and manufacturing of novel biologicals and biosimilar molecules, today announced that General Atlantic, a leading global growth equity firm, will invest US$55 million in primary capital in the Company. The investment will support KGBio’s ongoing clinical development and commercialization needs, asset acquisition plan, and production capacity expansion efforts.

KGBio’s ambition is to play a leading role in increasing biological and biosimilar drug availability in the Southeast Asia region. Founded as a joint venture between Kalbe Farma, a leading healthcare and pharmaceuticals company in Indonesia and Southeast Asia, and Genexine, a leading clinical-stage biotechnology company in South Korea, KGBio is positioned for strategic growth. A combination of factors, including affordability constraints and lack of local manufacturing capabilities, have slowed the penetration of biologicals in the region. Biologicals have emerged as an important category of drug development over the past 20 years, with breakthrough advances in disease management, particularly in areas such as immuno-oncology, a key focus area for the Kalbe Group and KGBio. KGBio has built robust capabilities in clinical development and manufacturing and plans to leverage Kalbe Farma’s strength in distribution and global networks to create a large portfolio of biologicals for the Southeast Asia region.

Irawaty Setiady, President Commissioner of Kalbe Farma, said, “Biologicals is a key growth lever for the Kalbe Group. As an R&D-driven organization, we are committed to bringing global innovation in medicine and improving the accessibility and affordability of critical drugs for patients across the Southeast Asia region. We welcome the opportunity to partner with General Atlantic, a leading global investor in life sciences, to help realize our vision in Southeast Asia and beyond.”

Sandeep Naik, Managing Director and Head of India & Southeast Asia at General Atlantic, said, “We admire KGBio’s vision to bring affordable, high-quality biological products to Southeast Asia and look forward to working in partnership with Kalbe Farma and Genexine to advance this mission. With significant existing momentum, we believe KGBio is positioned to becoming a leading biologics platform in the Southeast Asia region as the Company continues to scale.”

Dr. Sung Young-Chul, CEO of Genexine and commissioner of KGBio, said “We are very pleased to have General Atlantic come onboard as a partner in KGBio. Genexine shares Kalbe Farma’s vision to create a leading biotech platform for the Southeast Asia region. Our partnership with Kalbe to bring leading global biotechnology innovation has been very successful so far, and we look forward to the next phase of growth as this new alliance helps us bring our goal closer.”

Sie Djohan, Director of Kalbe Farma and CEO of KGBio, said, “Our partnership with General Atlantic represents a new milestone in KGBio’s growth trajectory beyond Indonesia and Southeast Asia. As a global player in life sciences, General Atlantic brings an extensive network and deep expertise in innovation that KGBio aims to leverage. Having made considerable progress in the clinical development, regulatory approvals and commercialization of our novel and biosimilar molecules, we aim to further expand our portfolio and reach with the support of Genexine and General Atlantic as our partners.”

Ashish Saboo, Managing Director and Head of Indonesia at General Atlantic, said, “KGBio is committed to meeting the challenging healthcare needs of the Southeast Asia region by providing effective, affordable treatments for chronic health conditions. The Company is underpinned by Kalbe Farma’s leading R&D and governance standards, strong portfolio, integrated facilities, experienced management team, and extensive distribution network, as well as Genexine’s clinical development expertise. We are thrilled to back KGBio on their journey to drive global biotechnology innovation.”

About Kalbe Genexine Biologics (KGBio)

KGBio aims to provide high-quality, affordable, and innovative biologics, biosimilars, and immuno-oncology products to the Southeast Asia market. KGBio was founded in 2016 as a joint venture between Kalbe Farma Tbk (IDX:KLBF), a leading pharma company in Indonesia and Southeast Asia, and Genexine (KOSDAQ: 095700), a South Korea-based clinical-stage biotechnology company.

KGBio has licensed two advanced clinical-stage biological drugs (PD-1 for various oncology indications, and a third-generation Erythropoietin for CKD-induced anemia) and one early clinical-stage novel biological drug:

  • PD-1 Antibody (HLX10): HLX10 is a humanized anti-PD1 monoclonal antibody. It is being evaluated for the treatment of multiple tumor indications, as well as chronic hepatitis B infections. KGBio has taken licenses for squamous non-small-cell lung cancer and hepatocellular carcinoma indications in which global phase III studies are in progress.
  • EPO hyFc (GX-E4): GX-E4 is a novel long-acting erythropoietin-hybrid Fc fusion protein. It is being evaluated in a phase III study for the treatment of anemia related to chronic kidney disease in Southeast Asian countries, Taiwan, and Australia.
  • CD73 Antibody (TJD5): TJD5 is a CD73-antagonistic antibody. CD73 is the rate-limiting enzyme that converts extracellular AMP to adenosine, a potent immunosuppressive molecule in the tumor micro-environment. TJD5 is being evaluated in a phase I study in combination with Atezolizumab.

KGBio fully owns Innogene Kalbiotech (“Innogene”) and holds a controlling stake in Kalbio Global Medika (“Kalbio”). Innogene is a biosimilar platform and currently has four monoclonal antibody drugs (Rituximab, Nimotuzumab, Trastuzumab, and Bevacizumab). Kalbio is a biological manufacturing facility with bioreactor capacity for mammalian cell-lines. For more information, please visit the website: www.kg-biologics.com.

About General Atlantic

General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to build market-leading businesses worldwide. General Atlantic has more than 175 investment professionals based in New York, Amsterdam, Beijing, Greenwich, Hong Kong, Jakarta, London, Mexico City, Mumbai, Munich, Palo Alto, São Paulo, Shanghai and Singapore. For more information on General Atlantic, please visit the website: www.generalatlantic.com.

About Genexine

Genexine, Inc. (KOSDAQ:095700) is a clinical stage biotechnology company, focused on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFcTM platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics, and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. For more information, please visit the website: www.genexine.com.

About Kalbe Farma

PT Kalbe Farma Tbk (IDX:KLBF) is a leading pharmaceuticals company in Indonesia and Southeast Asia. It was established in 1966 and is headquartered in Jakarta, Indonesia. Kalbe Farma operates in four main divisions: prescription pharmaceuticals, consumer health, nutrition, and distribution and logistics. For more information, please visit the website: www.kalbe.co.id.

Media Contacts

Mary Armstrong & Emily Japlon
General Atlantic media@generalatlantic.com

Categories: News

Tags:

Equality Health and General Atlantic Announce Strategic Partnership to Help Drive Continued Expansion of Equality’s Value-Based Primary Care Network and Technology Solutions

Strategic investment from General Atlantic to help enable Equality Health in furthering its mission of increasing access to care, lowering costs and improving outcomes for underserved individuals, families and communities

Equality Health to acquire actuarial firm, Daraja Services, to deepen healthcare economics capabilities

January 26, 2021

Equality Health (or “the Company”), a leading provider of technology, services and support for value-based care, today announced a strategic investment from General Atlantic, a leading global growth equity firm, to fuel the Company’s next phase of growth as a value-based primary care network serving the Medicaid, Medicare and ACA Exchange populations. Existing investor Endeavour Capital will remain a minority shareholder, and Town Hall Ventures will also invest in the Company. As part of the transaction, Equality Health will acquire Phoenix-based consulting firm Daraja Services and plans to integrate the firm’s suite of healthcare economics, technology and actuarial capabilities.

Equality Health was founded in Phoenix, Arizona in 2015 by CEO Hugh Lytle with the mission of improving access to culturally competent and holistic care for the Medicaid market, a population traditionally underserved by the U.S. healthcare system. Through its supplemental care management services and proprietary technology platform, CareEmpower™, the Company enables payors and providers to deliver a leading patient experience, while lowering the cost of care and improving member outcomes. Today, Equality Health networks represent more than 1,600 primary care providers across six metropolitan service areas in three states

Over the past five years, the Company has rapidly expanded its physician base and geographic reach in Arizona, California and Texas, supporting care for over 300,000 beneficiaries via partnerships with more than 20 managed care sponsors. Equality Health will leverage the partnership with General Atlantic to pursue further geographic expansion, technological innovation and product development in the near term, while also augmenting its actuarial and data analytics capabilities through the acquisition of Daraja Services.

Hugh Lytle, Founder and CEO of Equality Health, said, “Equality Health believes that high-quality, value-based care should be accessible to all individuals, families and communities across the U.S. We believe we can significantly accelerate this mission through our partnership with General Atlantic, leveraging the firm’s demonstrated experience in helping value-based care models scale. We are excited by the opportunity to further our momentum in transforming the space by leveraging technology to change behaviors, improve outcomes and increase affordability.”

“Equality Health is bringing much-needed technology innovation and care to the managed Medicaid sector,” continued Robbert Vorhoff, Managing Director and Global Head of Healthcare at General Atlantic. “As the Medicaid market continues to expand and shift toward managed care, we believe the company is positioned for substantial growth. Hugh and the Equality Health team have built a compelling model that delivers greater value to payors, providers and patients, and we’re proud to support their vision.”

J.P. Morgan acted as financial advisor to Equality Health. Perkins Coie LLP and Squire Patton Boggs acted as legal counsel. Paul, Weiss, Rifkind, Wharton & Garrison LLP served as legal counsel to General Atlantic. Additional terms of the deal were not disclosed.

About Equality Health

Equality Health, LLC is a Phoenix-based whole-health delivery system focused on transforming value-based care delivery with population specific programs that improve access, quality, and member trust. Through an integrated technology and services platform, culturally competent provider network and personalized care model, Equality Health helps managed care plans and health systems improve outcomes for diverse populations while simultaneously making the transition to risk-based accountability. For more information about Equality Health, visit www.equalityhealth.com or follow @EqualityHealth on Facebook, @EqualityHealth on Twitter, and @EqualityHealth on LinkedIn.

About General Atlantic

General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to build market-leading businesses worldwide. General Atlantic has more than 175 investment professionals based in New York, Amsterdam, Beijing, Greenwich, Hong Kong, Jakarta, London, Mexico City, Mumbai, Munich, Palo Alto, São Paulo, Shanghai and Singapore. For more information on General Atlantic, please visit the website: www.generalatlantic.com.

Media Contacts

Mary Armstrong & Emily Japlon
General Atlantic media@generalatlantic.com

Tomás León
Equality Health tleon@equalityhealth.com

Categories: News

Tags:

Investment in Idealista

Oakley
26 Jan 21

Oakley Capital (“Oakley”) is pleased to announce that Oakley Capital IV (“Fund IV”) has agreed to make a minority investment in idealista (the “Company”), the leading online real estate classifieds platform in Southern Europe, present in Spain, Italy, and Portugal. Fund IV will invest €175 million alongside the management team of idealista and EQT, who will remain the majority shareholders in the Company.

Fund IV’s investment in idealista will draw upon Oakley’s proven expertise in the online classifieds sector. Oakley has an in-depth understanding of idealista from Oakley Capital Private Equity III (“Fund III”)’s successful sale of Casa.it (“Casa”) to EQT in September 2020, which was subsequently combined with idealista’s Italian operations. The highly synergistic combination with Casa has strengthened the Company’s competitive positioning in Italy and is complementary to idealista’s market leading position in Spain and Portugal.

Founded in 2000 and headquartered in Madrid, Spain, idealista supports approximately 40,000 real estate agents and 38 million unique monthly visitors across Southern Europe by providing an online real estate classifieds marketplace for home buyers and sellers. The Company’s online platform and diversified portfolio of digital services, such as CRM tools, data analytics, and online mortgage brokerage, help facilitate efficient real estate transactions, making it a key destination for prospective homeowners and sellers in Spain, Italy, and Portugal. idealista is a clear leader in Spain and Portugal and has a growing presence in Italy, a market where the Company will benefit from Oakley’s previous experience with Casa.

idealista’s underlying market is supported by favourable secular megatrends, such as the increasing penetration of the online classifieds market in Italy, Spain and Portugal as they mature in line with more developed global classifieds markets; the shift from offline to online marketing spend by real estate agents; and the significant network effects driven by the platform’s strong brand recognition.

Jesús Encinar, Founder, Chairman & CEO of idealista, commented:
“We are very excited to partner with EQT and Oakley and look forward to working together during the coming years. EQT and Oakley’s online classifieds and real estate expertise will be of great value for us and key to our fut

Following our successful track record in the online real estate classifieds market, we believe that idealista has significant potential to further consolidate its market-leading position in Southern Europe. We look forward to working with EQT and idealista’s high-quality management team, and together supporting the business in this next stage of growth.
Peter Dubens
Managing Partner, Oakley Capital

ure success. We share a similar culture and passion for growth – a key decision factor for me and my team to partner with them.”

Categories: News

Tags: